AKT1 and lung carcinoma: Studies conducted in lung cancer have also documented increased expression and activation of integrin β1 and Src in erlotinib-resistant cells, suggesting that the integrin β1/Src/Akt signalling pathway may play a crucial role in conferring erlotinib resistance to lung cancer cells [27].